Hanmi Pharmaceutical said on the 30th that it achieved cumulative sales of 1.1146 trillion won for the first to third quarters by the third quarter of this year, marking top-line growth.
On a consolidation basis, third-quarter results were tentatively tallied as sales up 0.1% from a year earlier to 362.3 billion won, operating profit up 8% to 55.1 billion won, and net profit up 29.9% to 45.4 billion won.
The company said that management activities based on the stable professional management system established early this year are creating continued synergies across products, new drug research and development (R&D), and exports. It also said it invested 62.3 billion won, or 17.2% of third-quarter sales, in R&D to create future growth engines.
The company said that, along with revenue from sales of its mainstay improved and combination drugs, receipt of an advance payment under the technology transfer agreement for "Ensocuita" signed with Gilead Sciences Inc. in the United States contributed to improved profitability this quarter.
Third-quarter out-of-hospital prescription sales (UBIST reimbursement basis) rose 3% on-year to 256.5 billion won. The company projected it is likely to rank No. 1 in domestic out-of-hospital prescription sales for eight consecutive years from 2018 through this year.
Third-quarter out-of-hospital prescription sales of the dyslipidemia combination drug "Rosuzet" rose 10.1% on-year to 58.9 billion won; the hypertension product group "Amosartan Family" posted 37.0 billion won; and the gastroesophageal reflux disease product group "Esomezol Family" recorded 15.7 billion won. The new diabetes product "Daparon Family" increased 58.7% from a year earlier.
Several new products were also launched in the third quarter. Examples include the world's first low-dose triple antihypertensive "Amoprel," the osteoporosis treatment "Obodens," and the injectable influenza infection treatment "Hanmi Peramivir Injection."
There were also key results from the obesity new drug development project. The company recently announced interim phase 3 results confirming the safety and efficacy (treatment effect) of its lead pipeline "Efeglenatide."
Other obesity new drug candidates are also under development. The company said it is focusing on development with commercialization targets set for 2030 for the next-generation triple-acting obesity treatment (LA-GLP/GIP/GCG, HM15275) and 2031 for the novel-concept obesity treatment (LA-UCN2, HM17321).
Third-quarter sales at Beijing Hanmi Pharmaceutical, the company's local subsidiary in China, came to 94.1 billion won on a consolidation basis, with operating profit of 23.6 billion won, up 11.6% and 57.6%, respectively, from a year earlier, showing double-digit growth. Net profit was tallied at 21.2 billion won.
Chief Executive Park Jae-hyun of Hanmi Pharmaceutical said, "The third quarter was a meaningful period in which the solid growth of innovative products developed with Hanmi's proprietary technology and progress in global clinical development of new drugs combined to further strengthen our fundamentals," adding, "We will continue to expand our global presence based on Hanmi's brand competitiveness and further enhance the future value of our new drug pipeline to repay shareholders' expectations and support."